Recent News

• 11.14.2025 - Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
• 10.02.2025 - Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
• 09.17.2025 - Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
• 09.10.2025 - Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
• 08.13.2025 - Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
• 07.08.2025 - Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Recent Filings

• 11.07.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.07.2025 - 8-K Current report
• 09.17.2025 - 8-K Current report
• 09.10.2025 - 8-K Current report
• 08.25.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2025 - 8-K Current report